ClinicalTrials.gg

Program

KH607

A development code. Also written as “KH607 tablets”, “Part B: KH607” and “KH607 tablet”.

Its studies are mostly in Depressive Disorder, Major, led by Chengdu Kanghong Pharmaceutical Group.

Furthest: phase 3, since Jul 23, 20266 company-led studies, 4 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Kanghong Pharmaceutical Group64 open or runningphase 3since Jul 23, 2026Jan 4, 2024Dec 2027phase 3 · NCT07741331

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 4, 2024First study: phase 1 study in HealthyFirst studyNCT06393803 · 88 planned · China
  2. Jul 24, 20252 phase 2 studiesNCT07101120, NCT07096791
  3. May 27, 2026Phase 1 study in Food Effect of KH607 in Chinese Health ParticipantsNCT07634874 · 16 planned
  4. Jul 23, 20262 phase 3 studies in Depressive Disorder, MajorPhase 3 reachedNCT07741331, NCT07741240

Ahead

  1. Dec 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT07741331
  2. Dec 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT07741240

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07741331Depressive Disorder, Major3Not yet recruitingDec 2027326
NCT07741240Depressive Disorder, Major3Not yet recruitingDec 2027232
NCT07634874Food Effect of KH607 in Chinese Health Participants1Not yet recruitingJul 202616
NCT07101120Depressive Disorder, Major · China2CompletedFeb 9, 2026126
NCT07096791Postpartum Depressive Disorder · China2CompletedApr 24, 202672
NCT06393803Healthy · China1RecruitingOct 30, 202488

How it is read

Names in the registry

  • “KH607 tablets”, 6 entries
  • “KH607”, 2 entries
  • “Part B: KH607”, 1 entry
  • “KH607 tablet”, 1 entry
  • “2mg KH607 tablets”, 1 entry

Codes read as this program: KH607.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.